...
首页> 外文期刊>Integrative cancer therapies >Transient Receptor Potential Channel and Interleukin-17A Involvement in LTTL Gel Inhibition of Bone Cancer Pain in a Rat Model
【24h】

Transient Receptor Potential Channel and Interleukin-17A Involvement in LTTL Gel Inhibition of Bone Cancer Pain in a Rat Model

机译:瞬时受体电位通道和白介素17A参与大鼠模型的骨癌疼痛LTTL凝胶抑制

获取原文
获取原文并翻译 | 示例

摘要

Cancer pain management is a challenge for which Chinese herbal medicine might be useful. To study the spinal mechanisms of the Chinese medicated gel Long-Teng-Tong-Luo (LTTL), a 7-herb compound, on bone cancer pain, a bone cancer pain model was made by inoculating the tibias of female rats with Walker 256 cells. LTTL gel or inert gel, 0.5 g/cm(2)/d, was applied to the skin of tumor-bearing tibias for 21 days beginning a day after the inoculation. Mechanical threshold and paw withdrawal latency to thermal stimulation was measured. Transient receptor potential (TRP) cation channels in lumbar dorsal root ganglia (DRG) were immunostained and counted, and lumbar spinal cord interleukin-17A (IL-17A) was measured with real-time polymerase chain reaction and enzyme-linked immunosorbent assay. TRP antagonists and interleukin (IL)-17A antibodies were intrathecally administered to determine their effects on bone cancer pain. The gel significantly (P < .05) alleviated cancer-induced mechanical allodynia and thermal hyperalgesia and inhibited cancer-enhanced expression of IL-17A in spinal astrocytes and the TRP subfamily members V1, A1, and V4 in lumbar DRG. Intrathecal TRP antagonists at 10 mu g significantly (P < .05) attenuated mechanical allodynia, thermal hyperalgesia, and IL-17A expression, indicating that TRP channels facilitate spinal IL-17 expression and cancer pain. IL-17A antibodies inhibited cancer pain, suggesting that IL-17A promotes such pain. The data show that LTTL gel inhibits cancer pain, and this might be accounted for by the decrease in expression of DRG TRP channels and spinal astrocyte IL-17A.
机译:癌症疼痛的治疗是一个挑战,中草药可能会有用。为了研究中药凝胶龙腾通络(LTTL)(一种7草药化合物)对骨癌疼痛的脊髓机制,通过用Walker 256细胞接种雌性大鼠的胫骨来建立骨癌疼痛模型。从接种后的第二天开始,将LTTL凝胶或惰性凝胶0.5 g / cm(2)/ d涂在荷瘤胫骨皮肤上21天。测量机械阈值和对热刺激的爪缩回潜伏时间。免疫染色并计数腰背根神经节(DRG)中的瞬时受体电位(TRP)阳离子通道,并通过实时聚合酶链反应和酶联免疫吸附测定法测量腰脊髓白介素17A(IL-17A)。鞘内施用TRP拮抗剂和白介素(IL)-17A抗体,以确定它们对骨癌疼痛的影响。凝胶显着(P <.05)减轻了癌症引起的机械性异常性疼痛和热痛觉过敏,并抑制了脊髓星形胶质细胞和腰部DRG的TRP亚家族成员V1,A1和V4的癌症增强型IL-17A表达。鞘内10μg的TRP拮抗剂显着(P <.05)减弱了机械性异常性疼痛,热痛觉过敏和IL-17A的表达,表明TRP通道促进了脊柱IL-17的表达和癌痛。 IL-17A抗体抑制癌症疼痛,表明IL-17A促进了这种疼痛。数据显示LTTL凝胶可抑制癌症疼痛,这可能是由于DRG TRP通道和脊髓星形胶质细胞IL-17A的表达减少所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号